Date Initiated by Firm | May 12, 2020 |
Date Posted | July 10, 2020 |
Recall Status1 |
Terminated 3 on April 19, 2024 |
Recall Number | Z-2547-2020 |
Recall Event ID |
85744 |
510(K)Number | K141458 K150962 |
Product Classification |
Herpes simplex virus nucleic acid amplification assay - Product Code OQO
|
Product | MOL2150 Simplexa HSV 1&2 Direct
-CSF
-Genital Swab
-Cutaneous / Mucocutaneous Swabs
Product Usage: is intended for use on the LIAISON MDX instrument for the qualitative detection and differentiation of HSV-1 and HSV-2 present in cerebrospinal fluid (CSF), or cutaneous and mucocutaneous lesion swabs from patients with signs and symptoms of HSV-1 or HSV-2 infection of the central nervous system (CNS) or cutaneous and mucocutaneous lesions. |
Code Information |
MOL2150 Simplexa HSV 1&2 Direct:
Lot Numbers Release Date Exp Date
3606N 08/16/18 6/30/2020
3607N 08/31/18 6/30/2020
3609N 08/31/18 6/30/2020
3610N 10/08/18 7/31/2020
3615N 01/07/19 6/30/2020
3616N 11/28/18 6/30/2020
3618N 12/26/18 6/30/2020
3619N 12/26/18 6/30/2020
3847N 12/31/18 6/30/2020
3998N 07/20/18 5/31/2020
4000N 07/18/18 5/31/2020
4130N 03/05/19 6/30/2020
4131N 02/01/19 6/30/2020
4132N 02/15/19 6/30/2020
4134N 04/18/19 8/31/2020
4137N 04/04/19 8/30/2020
4138N 04/30/19 8/31/2020
4139N 07/12/19 5/31/2021
5171N 09/17/19 6/30/2021
5172N 09/03/19 6/30/2021
5173N 05/03/19 8/31/2020
5174N 06/04/19 8/31/2020
5175N 06/04/19 8/31/2020
5187N 07/19/19 5/31/2021
5188N 06/05/19 8/31/2020
5189N 07/25/19 5/31/2021
5190N 05/23/19 8/31/2020
5623N 07/25/19 5/31/2021
5738N 08/02/19 5/31/2021
5739N 08/20/19 6/30/2021
5793N 10/07/19 7/31/2021
5795N 03/09/20 12/31/2021
5841N 10/22/19 8/31/2021
5843N 10/31/19 8/31/2021
5845N 10/18/19 8/31/2021
5846N 04/06/20 1/31/2022
5846NA 04/16/20 1/31/2022
5847N 12/17/19 10/31/2021
5878N 03/11/20 1/31/2022
5888N 03/18/20 1/31/2022
R5170N 06/20/19 8/31/2020
R5201N 06/28/19 8/31/2020
R5202N 07/03/19 4/30/2021
R5283N 08/13/19 8/31/2020
R5285N 06/20/19 8/31/2020
|
Recalling Firm/ Manufacturer |
DiaSorin Molecular LLC 11331 Valley View St Cypress CA 90630-5366
|
For Additional Information Contact | 562-240-6500 |
Manufacturer Reason for Recall | Due to a software malfunction in the Multi Assay Suite, there is the probability of increased occurrence of false negative results. |
FDA Determined Cause 2 | Under Investigation by firm |
Action | On 05/12/2020, the firm sent an "URGENT FIELD SAFETY NOTIFICATION LETTER" with an acknowledgement form to customers and distributors via email to inform them of an internal observed issue associated with the use of their Multi-Assay Suite (MAS) featured in the software version 2.0 where it may incorrectly apply the thresholds of the first loaded assay to the analytes coupled with the same dye in the second assay resulting in false negative or false positive results.
The firm is instructing customers to:
-Immediately discontinue the use of the MAS feature and that the issue will be correct in the new Software Version 2.1 which is expected to be release in June 2020.
-Fill out the Response Form and return by either:
-fax (562) 240-6526 Attention: Technical Services
-email to: technical info.molecular@diasorin.com
-mail to: ATTN: Technical Services, 11331 Valley View Street, Cypress, CA 90630
-Forward this communication to all required individuals with their organization.
For further assistance with evaluating assay runs or for any questions, to contact Technical Services at +1-5672-240-6500, option 3 or via email ts.molecular@DiaSorin.com |
Quantity in Commerce | 13943 plastic vials (24 vials per box) |
Distribution | Worldwide distribution - U.S. Nationwide distribution including in the states of CO, FL, KS, MI, NC, PA, TX, and WA
The countries of Austria, Czech Republic, France and Switerland. |
Total Product Life Cycle | TPLC Device Report |
|
1 A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls. 2 Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall. 3 For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.
|
510(K) Database | 510(K)s with Product Code = OQO
|